Revenue

Indian pharma giant Lupin secures FDA approval for a generic heart drug, challenging AstraZeneca and signaling a new era of cost competition in specialty medicine.

With a fresh $16.2M, Chaince Digital is betting big on building regulated infrastructure for tokenization before institutional demand fully arrives.

Beyond the record revenue, Applied BioCode's growth reveals a strategy of solving lab bottlenecks and securing reimbursement, positioning it against industry giants.

Freedom Holding Corp. posts a 40% revenue jump but a drop in net income, signaling an aggressive, high-cost strategy centered on its SuperApp and major acquisitions.

A shocking $90M guidance cut and a securities probe at Myriad Genetics reveal more than a bad quarter; they expose deep cracks in the genetic testing market.

AGCO's stock plunged after a surprise guidance cut, triggering a legal probe. We dissect if this was just a market downturn or a failure in transparency.

The abrupt exit of President Heather Dixon and the return of a former COO raises critical questions about stability and long-term strategy at the home care giant.

Former World Bank President Dr. Jim Yong Kim joins ImmunityBio. Is this a new model for biotech social impact or a high-stakes bet on global expansion?

As SKYX Platforms preps its Q2 earnings call, investors look beyond the numbers to its patent moat, e-commerce engine, and leadership's execution strategy.

A new wave of eco-friendly tech is shifting the fight against wildfires from reaction to prevention, forging alliances from fire departments to insurance giants.

Christopher Nolan's 'The Odyssey' has become IMAX's biggest film ever, driving record profits and showcasing groundbreaking camera technology.

Outdoor Holding Company's Q1 results show a stunning recovery. With revenue up 22% and profits secured, its GunBroker platform is outperforming the market.

Hyosung’s impressive H1 2026 results reveal a shrewd strategy: localizing US power grid production for the AI boom while betting on bio-textiles and humanists.

Heron Therapeutics withdraws guidance after a patent blow to its top drug, forcing a strategic review. Can strong growth in new acute care products save it?

Revenue missed and its stock plunged, but Quanterix is betting on a new C-suite and its Alzheimer's test to navigate market headwinds and deliver on its promise.

Amid its pending sale to Zymeworks, Theravance Biopharma’s Q2 results reveal a lesson in resilience, with strong YUPELRI sales and deep cost cuts.

CECO Environmental's record quarter, fueled by a mega-acquisition, reveals a complex story of ambition, financial nuance, and a strategic pivot to dominate.

The work management giant posted strong Q2 results but is betting its future on a radical AI pivot, cutting staff to fund a new era of automated execution.

Strive, Inc. reports a massive Q2 loss on paper, but a closer look reveals a debt-free company doubling down on Bitcoin and launching a daily dividend.

With eight straight quarters of growth, Citi Trends' success isn't just about off-price value. It's a masterclass in strategic focus on a core demographic.